Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a ...

If you are wondering whether Regeneron Pharmaceuticals at around US$758.91 represents fair value or a potential opportunity ...

What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have ...

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

While the company is making efforts to diversify its revenue base and develop its oncology franchise, Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ ...

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 96.18 with a ...

Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...

Regeneron Pharmaceuticals Inc. stock reached a significant milestone, hitting a 52-week high of $795.88. This achievement underscores a positive trend for the biotechnology company, reflecting a ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals, Inc. delivered a strong Q3 earnings beat, driven by Dupixent growth, despite ongoing Eylea sales declines and manufacturing setbacks. REGN's future growth is anchored by ...